Key result
Genetic syndromes in pediatric CHD linked to ~13-fold higher hematopoietic cancer risk.
Why the study?
Reliable risk estimates of hematopoietic cancer among children with congenital heart disease based on large population-based data remained scant.
Does the presence of a known genetic syndrome increase the risk and cumulative incidence of hematopoietic cancer in children with congenital heart disease?
Cohort (n=143,794)
Yes
Does the presence of a known genetic syndrome increase the risk and cumulative incidence of hematopoietic cancer in children with congenital heart disease?
Answers are grounded in this paper and cite their sources.
Children with congenital heart disease and known genetic syndromes have a 13.4-fold increased risk of developing hematopoietic cancer compared with the general pediatric population (reaching 23.2-fold in Down syndrome), highlighting the need for targeted early cancer surveillance in this population.
BACKGROUND: Individuals with genetic syndromes can manifest both congenital heart disease (CHD) and cancer attributable to possible common underlying pathways. To date, reliable risk estimates of hematopoietic cancer (HC) among children with CHD based on large population-based data remain scant. This study sought to quantify the risk of HC by the presence of genetic syndrome among children with CHD. METHODS AND RESULTS: Data sources were the Canadian CHD database, a nationwide database on CHD (1999-2017), and the CCR (Canadian Cancer Registry). Standardized incidence ratios were calculated for comparing HC incidences in children with CHD with the general pediatric population. A modified Kaplan-Meier curve was used to estimate the cumulative incidence of HC with death as a competing risk. A total of 143 794 children (aged 0-17 years) with CHD were followed up from birth to age 18 years for 1 314 603 person-years. Of them, 8.6% had genetic syndromes, and 898 HC cases were observed. Children with known syndromes had a substantially higher risk of incident HC than the general pediatric population (standardized incidence ratio, 13.4 [95% CI, 11.7-15.1]). The cumulative incidence of HC was 2.44% (95% CI, 2.11-2.76) among children with a syndrome and 0.79% (95% CI, 0.72-0.87) among children without a syndrome. Acute myeloid leukemia had a higher cumulative incidence during early childhood than acute lymphoblastic leukemia. CONCLUSIONS: This is the first large population-based analysis documenting that known genetic syndromes in children with CHD are a significant predictor of HC. The finding could be essential in informing risk-stratified policy recommendations for cancer surveillance in children with CHD.
No takes yet. Share an insight, caveat, or question.
Hasan et al. (2023) conducted a cohort in Congenital heart disease (n=143,794). Known genetic syndromes (e.g., Down syndrome, Noonan syndrome) vs. Children with congenital heart disease without genetic syndromes and the general Canadian pediatric population was evaluated on Incident hematopoietic cancer (first hospitalization with primary or secondary discharge diagnosis of primary HC) (SIR 13.4, 95% CI 11.7-15.1). Genetic syndromes in children with congenital heart disease increased hematopoietic cancer risk vs the general pediatric population.
Synapse has enriched 10 related papers. Consider them for comparative context: